February 2022 - Volume 81 - 2

EDITORIAL

1. Epigenetic profiling of twins identify repression of KLF4 as a novel pathomechanism in systemic sclerosis 

RHEUMATOID ARTHRITIS

2. Baseline predictors of different types of treatment success in rheumatoid arthritis 

3. Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies 

4. Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course (30 August, 2021)

5. Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables

6. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years 

7. Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis 

8. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials 

INFLAMMATORY ARTHRITIS

9. Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis 

PSORIATIC ARTHRITIS

10. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial 

IMAGING

11. Very low prevalence of ultrasound-detected tenosynovial abnormalities in healthy subjects throughout the age range: OMERACT ultrasound minimal disease study 

12. Choose wisely: imaging for diagnosis of axial spondyloarthritis 

SYSTEMIC LUPUS ERYTHEMATOSUS

13. Genomic sequencing and functional analyses identify MAP4K3/GLK germline and somatic variants associated with systemic lupus erythematosus 

14. Human SLE variant NCF1-R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages

SYSTEMIC SCLEROSIS

15. Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis 

AUTOIMMUNITY

16. Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease 

LETTERS

17. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

18. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series 

19. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series 

20. Inactivated vaccines may not provide adequate protection in immunosuppressed patients with rheumatic diseases 

21. Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis 

22. Fat mass and response to TNFα blockers in early axial spondyloarthritis: an analysis of the DESIR cohort 

23. Anti-ANP32A antibodies in systemic sclerosis 

ELECTRONIC PAGES

24. The cost of arthralgia ‘pretreatment’ to prevent rheumatoid arthritis 

25. Response to: ‘The cost of arthralgia ‘pretreatment’ to prevent rheumatoid arthritis’ by Rothschild 

26. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report

27. Response to: ‘Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report’ by Bader-Meunier et al 

28. Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity? 

29. Response to: ‘Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?’ by Teng et al 

30. Dupilumab as a potential steroid-sparing treatment for IgG4-related disease

31. Response to: ‘Dupilumab as a potential steroid-sparing treatment for IgG4-related disease’ by Della-Torre et al 

32. Correspondence on: ‘Dupilumab as a novel steroid-sparing treatment for IgG4-related disease’ by Simpson et al 

33. Response to: ‘Correspondence on: ‘Dupilumab as a novel steroid-sparing treatment for IgG4-related disease’ by Simpson et al’ by Ebbo et al 

34. Interleukin-4 as an emerging therapeutic target for IgG4-related disease 

35. Response to : ‘Interleukin-4 as a emerging target for IgG4-related disease’ by Akiyama et al 

36. Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serum 

37. Response to: ‘Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serum’ by Gao et al 

38. Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database 

39. A case of episodic and refractory arthritis due to a novel variant of NLRP12 

40. Correction: Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

PDF

41. Correction: Emergent high fatality lung disease in systemic juvenile arthritis

PDF

ISSUE INFORMATION